

LIMITED REVIEW REPORT
FOR THE QUARTER ENDED ON 30TH SEPTEMBER 2014

We have reviewed the accompanying statement of unaudited financial results of **M/S. BIOFIL CHEMICALS & PHARMACEUTICALS LTD** (CIN L24233MP1985PLC002709) for the quarter ended 30th September 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.
Chartered Accountants
(Registration No: 002052C)



(S.N.Gadiya)
Proprietor

Membership No: 71229

Place: Indore
Date : 14/11/2014



BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30-09-2014
CIN NO. L24233MP1985PLC002709

(In Rs.)

Standalone / Consolidated Statement of Assets and		As At	As at
Liabilities		(Current year end)	(Current year end)
	Particulars	30/09/2014	31/03/2014
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	(82103795)	(84108795)
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	80634205	78629205
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	27074958	28705158
	(b) Trade payables	35712238	36357692
	(c) Other current liabilities		
	(d) Short-term provisions	690042	2294621
	Sub-total Current liabilities	63477238	67357471
	TOTAL - EQUITY AND LIABILITIES	144111443	145986676
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assests	90619634	91732634
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	90619634	91732634
2	Current assets		
	Current investments		
	Inventories	2624670	2735670
	Trade receivables	38930111	41041109
	Cash and cash equivalents	1726747	1792975
	Short-term loans and advances	7701623	6153148
	Other current assets	2508658	2531139
	Sub-total - Current assets	53491809	54254042
	TOTAL - ASSETS	144111443	145986676

DATE : 14/11/2014

PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Ramesh Shah
RAMESH SHAH
 MANAGING DIRECTOR
 (DIN NO. 00028819)



Un-Audited Financial Results of Quarter Ended Sep . 2014
30-09-2014 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN NO. L24233MP1985PLC002709

Un-AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30th September , 2014

PART I		Rs. In Lakhs					
	Particulars	Quarter Ended			Hald Year Ended		Year Ended
		Sep-14	Jun-14	Sep-13	Sep-14	Sep-13	Mar-14
	(Refer Notes Below)	Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
1	Income from operations						
	(a) Net sales/ income from operations (Net of Excise duty)	71.71	50.05	91.17	121.76	178.88	488.88
	(b) Other operating income						228.28
	Total income from operations (net)	71.71	50.05	91.17	121.76	178.88	717.17
2	Expenses						
	(a) Cost of materials consumed	20.87	13.28	61.54	34.15	113.26	153.78
	(b) Purchases of stock-in-trade	15.83	20.90	20.86	36.73	44.58	308.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.25)	2.14	(13.25)	(1.11)	(25.50)	18.17
	(d) Employee benefits expense	7.06	6.32	6.02	13.38	12.32	41.30
	(e) Depreciation and amortisation expense	5.57	5.56	5.25	11.13	10.50	22.23
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	6.90	7.68	5.22	14.58	10.93	99.14
	Total expenses	52.97	55.89	85.64	108.86	166.08	642.73
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	18.75	(5.84)	5.53	12.91	12.80	74.44
4	Other income		14.63	1.05	14.63	2.10	5.98
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	18.75	8.79	6.58	27.54	14.90	80.42
6	Finance costs	3.75	3.75	3.75	7.50	7.50	15.36
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	15.00	5.04	2.83	20.04	7.40	65.06
8	Exceptional items						1.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	15.00	5.04	2.83	20.04	7.40	64.06
10	Tax expense						12.40
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	15.00	5.04	2.83	20.04	7.40	51.66
12	Minority interest *						
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	15.00	5.04	2.83	20.04	7.40	51.66
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10	10
15	Reserve excluding Revaluation Reserves						-1220.02
16.i	Earnings per share (before extraordinary items)						
	(of Rs. 10/- each) (not annualised):						
	(a) Basic	0.0092	0.0031	0.0017	0.0123	0.0045	0.0317
	(b) Diluted						



See accompanying note to the financial results

\\ 2 \\

PART II

	Particulars	Sep-14	Jun-14	Sep-13	Sep-14	Sep-13	Mar-14
		Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares	8655100	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18	53.18
2	Promoters and Promoter Group Shareholding **						
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non - encumbered						
	- Number of shares	7618700	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82	46.82


	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	Nil

Notes

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 14th November 2014
2. Figures have been regrouped wherever necessary.
3. The Statuary auditors have carried out a limited review of the result for quarter ended 30th Sep- 2014

Date : 14.11.2014

Place : indore


RAMESH SHAH
MANAGING DIRECTOR



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results an Capital Employed for half year ended 30th Sep 2014
(Under Clause 41 Listing Agreement)

Quarter Ended

Rs. In lacs

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		31 March 2014
		Sep 30 , 2014	June 30 , 2014	Sep 30 , 2013	Sep 30 , 2014	Sep 30 , 2013	
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
		30.09.2014	30-06-2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
1	Segment Revenue						
	Pharma Unit	20.13	27.23	20.04	47.36	36.50	545.97
	Chemicals Division	48.71	14.60	46.80	63.31	103.17	144.65
	Plastic Division	2.87	8.22	23.84	11.09	38.74	26.54
	Other	0.00	14.63	1.05	14.63	2.10	6.49
	Gross Turnover	71.71	64.68	91.74	136.39	180.52	723.66
2	Segment Results						
	Pharma Unit	(2.51)	15.26	(1.23)	12.75	(2.48)	158.29
	Chemicals Division	22.80	(3.07)	9.27	19.73	21.09	(72.58)
	Plastic Division	(1.53)	(3.40)	(1.46)	(4.93)	(3.71)	(7.52)
	Other	0.00	0.00	0.00	0.00	0.00	1.12
	Total Segment Profit Before Tax	18.76	8.79	6.58	27.55	14.90	79.31
	Interest Income	0.00	0.00	0.00	-	-	0.43
	Interest Expenses	3.75	3.75	3.75	7.50	7.50	15.07
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	15.01	5.04	2.83	20.04	7.39	64.67
	Provision for current tax	0.00	0.00	0.00	-	-	12.32
	Profit After Tax	15.01	5.04	2.83	20.04	7.39	51.35
3	Capital Employed						
	(Segment Assets- Segment Liabilities)						
	Pharma Unit	220.71	46.01	246.45	220.71	246.45	137.25
	Chemicals Division	440.74	732.09	554.49	440.74	554.49	689.52
	Plastic Division	(25.06)	(39.55)	(15.96)	(25.06)	(15.96)	(52.88)
	Other	(2.21)	(3.86)	(51.55)	(2.21)	(51.55)	-
	Total Capital Employed	634.18	734.69	733.42	634.18	733.42	773.90

DATE : 14-11-2014
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Ramesh Shah
RAMESH SHAH
MANAGING DIRECTOR

